James Raftery: NICE changes its position on Alzheimer’s disease drugs

The provisional guidance from NICE on drugs for Alzheimers’ disease – donepezil, galantamine, rivastigmine, and memantine –  marks a dramatic shift from restricting access to those with moderate disease to  recommending these drugs as options for all patients with the disease. What has changed? No new compelling evidence has emerged. For each of the drugs […]

Read More…

Desmond O’Neill: Social networking, telemedicine, and stroke

Some medical technologies creep up on you, some arrive with a bang. In internal medicine much of the change – electronic laboratory reporting, digital imaging – is gradualist and steered by other disciplines, and physicians are grateful if relatively passive users. On the other hand, telemedicine for stroke thrombolysis was a radical step for both […]

Read More…

Martin McShane: Yes Minister

I used to love Yes Minister.  The civil service is full of very clever and erudite people who are hugely creative. Their brilliance shines through in the guidance just issued to PCTs and clinical commissioning groups on strategies to achieve cost-effective prescribing.  As it says in the widely circulated Chief Executive’s Bulletin, “This guidance reflects […]

Read More…